BERGER MONTAGUE Announces That A Securities Fraud Class Action Lawsuit Was Filed Against Fulgent Genetics, Inc. (NASDAQ: FLGT); Lead Plaintiff Deadline is November 21, 2022

PHILADELPHIA, PA / ACCESSWIRE /September 23, 2022 / Berger Montague informs investors that a securities fraud class action lawsuit has been filed against Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ:FLGT) on behalf of those who purchased Fulgent securities between securities between March 22, 2019 and August 4, 2022, both dates inclusive (the “Class Period”).

Investor Deadline: Investors who purchased or acquired Fulgent securities between March 22, 2019 and August 4, 2022 may no later than November 21, 2022, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at [email protected] or (215) 875-3093, or Andrew Abramowitz at [email protected] or (215) 875-3015 or visit: https://investigations.bergermontague.com/fulgent-genetics-inc/

According to the complaint, on August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing, among other items, that the SEC was investigating certain of Fulgent’s reports filed with the SEC from 2018 through the first quarter of 2020. The release followed Fulgent’s receipt of a civil investigative demand issued by the US Department of Justice “related to its investigation of allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law.”

Following this news, Fulgent’s stock price fell $11.02 per share, or 17.29%, over the following two trading days, to close at $52.72 per share on August 8, 2022.

Whistleblowers: Anyone with non-public information regarding Fulgent is encouraged to confidentially assist Berger Montague’s investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member

Berger Montague, with offices in Philadelphia, Minneapolis, Washington, DC, and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts:

James Maro, Senior Counsel
Berger Montagu
(215) 875-3093
[email protected]

Andrew Abramowitz, Senior Counsel
Berger Montagu
(215) 875-3015
[email protected]

SOURCE: Berger Montagu

View source version on accesswire.com:
https://www.accesswire.com/717291/BERGER-MONTAGUE-Announces-That-A-Securities-Fraud-Class-Action-Lawsuit-Was-Filed-Against-Fulgent-Genetics-Inc-NASDAQ-FLGT-Lead- Plaintiff-Deadline-is-November-21-2022

Comments are closed.